ACM
SMMT icon

ADAR1 Capital Management’s Summit Therapeutics SMMT Stock Holding History

ADAR1 Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-100,000
Closed -$2.13M – 256
2025
Q2 		$2.13M Hold
100,000
– – 0.33% 53
2025
Q1 		$1.93M Buy
+100,000
New +$2.01M 0.36% 60

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ADAR1 Capital Management's SMMT Position: Q1 2026 in Review

ADAR1 Capital Management held its Summit Therapeutics (SMMT) position steady in Q1 2026 at 91,869 shares worth $1.74M. The position accounts for 0.1% of the portfolio, ranked #124.

ADAR1 Capital Management first reported a position in SMMT in Q2 2025 and has held it in 4 quarters since. The position peaked at $2.13M in Q3 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • ADAR1 Capital Management held 91,869 shares of Summit Therapeutics worth $1.74M as of Q1 2026.
  • ADAR1 Capital Management left its Summit Therapeutics share count unchanged in Q1 2026.
  • Summit Therapeutics made up 0.1% of ADAR1 Capital Management's portfolio in Q1 2026, its #124 holding.
  • ADAR1 Capital Management first reported a position in Summit Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • ADAR1 Capital Management's Summit Therapeutics position peaked at $2.13M in Q3 2025.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.